ir_header
Current stock value

Last updated on Mar 27, 2015 4:00 PM ET

NASDAQ : SPHS 0.59   
+ 0.05
  
9.24%

Investor Presentation

PDF Download the Sophiris Investor Presentation


Investors

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of BPH and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris plans to initiate a Phase 2 proof of concept study of PRX302 for the treatment of localized low to intermediate risk prostate cancer during the first half of 2015. For more information, please visit www.sophiris.com.

View all »   RSSRecent Releases

Mar 10, 2015
Sophiris Bio Reports Fourth Quarter and Full Year Financial Results

Jan 29, 2015
Sophiris Bio to Present at the Leerink Global Healthcare Conference